Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis

Abstract

BackgroundThere are insufficient data from nationwide surveys on the prevalence of specific psychotic disorders and associated co-morbidities.MethodThe 2010 Australian national psychosis survey used a two-phase design to draw a representative sample of adults aged 18–64 years with psychotic disorders in contact with public treatment services from an estimated resident population of 1 464 923 adults. This paper is based on data from 1642 participants with an International Classification of Diseases (ICD)-10 psychotic disorder. Its aim is to present estimates of treated prevalence and lifetime morbid risk of psychosis, and to describe the cognitive, physical health and substance use profiles of participants.ResultsThe 1-month treated prevalence of psychotic disorders was 3.10 cases per 1000 population aged 18–64 years, not accounting for people solely accessing primary care services; lifetime morbid risk was 3.45 per 1000. Mean premorbid intelligence quotient was approximately 0.5 s.d.s below the population mean; current cognitive ability (measured with a digit symbol coding task) was 1.6 s.d.s below the population mean. For both cognitive tests, higher scores were significantly associated with better independent functioning. The prevalence of the metabolic syndrome was high, affecting 60.8% of participants, and pervasive across diagnostic groups. Of the participants, two-thirds (65.9%) were current smokers, 47.4% were obese and 32.4% were sedentary. Of the participants, half (49.8%) had a lifetime history of alcohol abuse/dependence and 50.8% lifetime cannabis abuse/dependence.ConclusionsOur findings highlight the need for comprehensive, integrative models of recovery to maximize the potential for good health and quality of life for people with psychotic illness.

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders

“…With respect to schizophrenia (a subgroup of the psychotic disorders), the estimated lifetime morbid risk (age range 18-45) is 2.37 per 1000 population (Morgan et al, 2014). The frequency of schizophrenia in Australian Indigenous communities is unknown, but higher rates of admission to psychiatric hospitals, as well as the effects of pervasive social disadvantage, suggest that the prevalence may be higher among Aboriginal people than in the wider society (Hunter, 2013).…”

Schizoaffective disorder and metabolic syndrome: A meta-analytic comparison with schizophrenia and other non-affective psychoses

“…Thirty studies were included for meta-analyses (Arango et al, 2008;Boden et al, 2013;Burghardt et al, 2014;Carr a et al, 2014;Centorrino et al, 2012;Cerit et al, 2008;Correll et al, 2014;Curtis et al, 2011;Elgamal et al, 2012;Gladigau et al, 2014;Gulec Oyekcin, 2009;Hatata et al, 2009;Holt et al, 2010;John et al, 2009;Keenan et al, 2013;Khatana et al, 2011;Kuzman et al, 2011;Lin et al, 2012;Mackin et al, 2007;MedeirosFerreira et al, 2013;Miller et al, 2013;Morgan et al, 2014;Pantusa et al, 2010;Risselada et al, 2012;Roshdy, 2011;Schorr et al, 2009;Steylen et al, 2009;Tseng et al, 2014;van Winkel et al, 2008;Wysokinski et al, 2012), using also unpublished data provided by corresponding authors (Boden et al, 2013;Burghardt et al, 2014;Carr a et al, 2014;Cerit et al, 2008;Correll et al, 2014;Curtis et al, 2011;Gladigau et al, 2014;Keenan et al, 2013;Kuzman et al, 2011;Lin et al, 2012;Mackin et al, 2007;<...>…”

Awareness of Pre-diabetes or Diabetes and Associated Factors in People With Psychosis

“…The design and methodology have been described in full elsewhere. 14 The research protocol for the study was approved by relevant institutional ethics committees and, after complete description of the study to the subjects, written informed consent was obtained.…”